including a recent approval in neoadjuvant/adjuvant treatment of early-stage non-small cell lung cancer (NSCLC). It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a ...

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous ... but picked up its first approval in the rare tumour Merkel cell carcinoma last year. Incyte had previously ...

Purpose: This study aims to investigate the efficacy and safety of PD-1/PD-L1 inhibitors in the first-line ... ((esophageal squamous cell carcinoma) OR (esophageal squamous cell cancer) OR (esophageal ...

Crown BioScience experts explore organoid models and high-content imaging to evaluate T-cell-targeted therapies and ...

Kanazawa University and colleagues have developed a promising new approach to cancer treatment. By using tiny, naturally ...

“Checkpoint inhibitor resistance remains ... 20 patients with PD-(L)1 non-responsive microsatellite stable (MSS) Colorectal Cancer (CRC) were included to assess potential activity in “cold ...

Thanks to the tireless efforts of people like San Luis Obispo resident Frank Kalman and his nonprofit, End Kids Cancer, there have been major advances in pediatric oncology in recent years. Here's Kal ...

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...

WITH an impressive attendance of 20,522 participants from 131 countries, the European Congress of Radiology (ECR) 2025 was an ...